SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-026973
Filing Date
2023-08-07
Accepted
2023-08-07 09:30:27
Documents
59
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 906301
2 ex31-1.htm EX-31.1 11373
3 ex31-2.htm EX-31.2 11114
4 ex32-1.htm EX-32.1 4113
5 ex32-2.htm EX-32.2 3973
  Complete submission text file 0001493152-23-026973.txt   4985713

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE gtbp-20230630.xsd EX-101.SCH 38522
7 XBRL CALCULATION FILE gtbp-20230630_cal.xml EX-101.CAL 40081
8 XBRL DEFINITION FILE gtbp-20230630_def.xml EX-101.DEF 172507
9 XBRL LABEL FILE gtbp-20230630_lab.xml EX-101.LAB 327196
10 XBRL PRESENTATION FILE gtbp-20230630_pre.xml EX-101.PRE 266093
53 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 741372
Mailing Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005
Business Address 8000 MARINA BLVD SUITE 100 BRISBANE CA 94005 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40023 | Film No.: 231145910
SIC: 2834 Pharmaceutical Preparations